Search

Your search keyword '"Beyne-Rauzy, O."' showing total 661 results
Start Over Author "Beyne-Rauzy, O."
661 results on '"Beyne-Rauzy, O."'

101. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N. Finelli, C. Della Porta, M. Fenaux, P. Ganser, A. Guerci-Bresler, A. Schmid, M. Taylor, K. Vassilieff, D. Habr, D. Domokos, G. Roubert, B. Rose, C. Agaoglu, L. Alimena, G. Alonso, D. Ame, S. Angelucci, E. Arrizabalaga, B. Athanasiou-Metaxa, M. Augustson, B. Aydinok, Y. Baba, A. Baccarani, M. Beck, J. Beris, P. Beyne-Rauzy, O. Birgens, H. Bordessoule, D. Borgna-Pignatti, C. Bosly, A. Bouabdallah, K. Bowden, D. Bowen, D. Bron, D. Cappellini, M.D. Capra, M. Cartron, G. Cazzola, M. Chalkias, C. Chan, L.L. Chancharunee, S. Chapman, C. Charoenkwan, P. Chasapopoulou, E. Cheze, S. Chuansumrit, A. Cianciulli, P. Dauriac, C. Delforge, M. Dölken, G. Dombret, H. Duyster, J. Economopoulos, T. Ehninger, G. Elalfy, M. El-Beshlawy, A. Enggaard, L. Fillet, G. Filosa, A. Forni, G. Galanello, R. Gastl, G. Giraudier, S. Goldfarb, A. Grigg, A. Gumruk, F. Ha, S.Y. Haase, D. Heinrich, B. Hertzberg, M. Ho, J. Hsu, H.-C. Huang, S. Hunault-Berger, M. Inusa, B. Jaulmes, D. Jensen, J. Kattamis, A. Kilinc, Y. Kim, K.-H. Kinsey, S. Kjeldsen, L. Koren, A. Lai, M.E. Lai, Y. Lee, J.-W. Lee, K.-H. Lee, S.-H. Legros, L. Li, C. Li, C.-K. Li, Q. Lin, K.-H. Linkesch, W. Lübbert, M. Lutz, D. Mohamed Thalha, A.J. Mufti, G. Muus, P. Nobile, F. Papadopoulos, N. Perrotta, S. Petrini, M. Pfeilstöcker, M. Piga, A. Poole, J. Porter, J.B. Pungolino, E. Quarta, G. Ravoet, C. Jolimont Lobbes, H.H. Remacha, A.F. Roy, L. Saglio, G. Sanz, G. Schmugge, M. Schots, H. Secchi, G. Seymour, J.F. Shah, F. Shah, H. Shen, Z. Slama, B. Sutcharitchan, P. Taher, A. Tamary, H. Tesch, H.-J. Thein, S.L. Troncy, J. Villegas, A. Viprakasit, V. Wainwright, L. Wassmann, B. Wettervald, M. Will, A. Wörmann, B. Wright, J. Yeh, S.-P. Yoon, S.-S. Zoumbos, N.C. Zweegman, S.

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

103. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Author

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B., Rose, C., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Cappellini, M. D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chan, L. L., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Elalfy, M., El Beshlawy, A., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Giraudier, S., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kattamis, A., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, J. W., Lee, K. H., Lee, S. H., Legros, L., Li, C., C. K., Li, Li, Q., Lin, K. H., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Seymour, J. F., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Taher, A., Tamary, H., Tesch, H. J., Thein, S. L., Troncy, J., Villegas, A., Viprakasit, V., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., Zweegman, S., Gattermann, N, Finelli, C, Porta, Md, Fenaux, P, Ganser, A, GUERCI BRESLER, A, Schmid, M, Taylor, K, Vassilieff, D, Habr, D, Domokos, G, Roubert, B, Rose, C, EPIC study, Investigator, Perrotta, Silverio, Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, Baccarani M, EPIC study investigators., and Çukurova Üniversitesi

Subjects
Male, Pediatrics, Cancer Research, Blood transfusion, Thalassemia, medicine.medical_treatment, Gastroenterology, Benzoates, Child, Hematology, biology, Benzoic Acids, Alanine Transaminase, Adolescent, Adult, Aged, Blood Transfusion, Preschool, Female, Ferritins, Humans, Iron Chelating Agents, Iron Overload, Middle Aged, Myelodysplastic Syndromes, Triazoles, Young Adult, Oncology, Child, Preschool, medicine.drug, medicine.medical_specialty, Myelodysplastic syndromes, deferasirox, iron chelation therapy, labile plasma iron, myelodysplastic syndromes, serum ferritin, Serum ferritin, Deferasirox, Iron chelation therapy, Labile plasma iron, Internal medicine, medicine, Adverse effect, iron-overloaded patients, transfusion, Labile plasmairon, business.industry, medicine.disease, Discontinuation, Iron chelationtherapy, Alanine transaminase, biology.protein, business, Myelodysplastic syndrome
Abstract

PubMedID: 20451251 The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ~50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Published
2010

104. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

Author

Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), Fenaux, P. (Pierre), Giagounidis, A. (Aristoteles), Mufti, G.J. (Ghulam), Mittelman, M. (Moshe), Sanz, G. (Guillermo), Platzbecker, U. (Uwe), Muus, P. (P.), Selleslag, D., Beyne-Rauzy, O. (Odile), Boekhorst, P.A.W. (Peter) te, Cañizo, C. (Consuelo) del, Guerci-Bresler, A. (Agnes), Nilsson, L. (Lars), Lübbert, M. (Michael), Quesnel, B. (Bruno), Ganser, A. (Arnold), Bowen, D. (David), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Fu, T. (Tommy), Benettaib, B. (Bouchra), Hellström-Lindberg, E. (Eva), and Fenaux, P. (Pierre)

Abstract

Objective: A subset analysis of the randomised, phase 3, MDS-004 study to evaluate outcomes in patients with International Prognostic Scoring System (IPSS)-defined Low-/Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with isolated del(5q). Methods: Patients received lenalidomide 10 mg/d (days 1-21; n = 47) or 5 mg/d (days 1-28; n = 43) on 28-d cycles or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or 10 mg at 16 wk, respectively. Results: Rates of red blood cell-transfusion independence (RBC-TI) ≥182 d were higher in the lenalidomide 10 mg (57.4%; P < 0.0001) and 5 mg (37.2%; P = 0.0001) groups vs. placebo (2.2%). Cytogenetic response rates (major + minor responses) were 56.8% (P < 0.0001), 23.1% (P = 0.0299) and 0%, respectively. Two-year cumulative risk of acute myeloid leukaemia progression was 12.6%, 17.4% and 16.7% in the lenalidomide 10 mg, 5 mg, and placebo groups, respectively. In a 6-month landmark analysis, overall survival was longer in lenalidomide-treated patients with RBC-TI ≥182 d vs. non-responders (P = 0.0072). The most common grade 3-4 adverse event was myelosuppression. Conclusions: These data support the clinical benefits and acceptable safety profile of lenalidomide in transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with isolated del(5q).

Published
2014
Full Text
View/download PDF

105. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Author

Cappellini, M. D., Porter, J., El Beshlawy, A., C. K., Li, Seymour, J. F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J. W., Chan, L. L., Lin, K. H., Rose, C., Taher, A., Thein, S. L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Agaoglu, L., Alimena, G., Alonso, D., Ame, S., Angelucci, E., Businco, A., Arrizabalaga, B., Athanasiou Metaxa, M., Augustson, B., Aydinok, Y., Baba, A., Baccarani, M., Beck, J., Beris, P., Beyne Rauzy, O., Birgens, H., Bordessoule, D., Borgna, Caterina, Bosly, A., Bouabdallah, K., Bowden, D., Bowen, D., Bron, D., Capra, M., Cartron, G., Cazzola, M., Chalkias, C., Chancharunee, S., Chapman, C., Charoenkwan, P., Chasapopoulou, E., Cheze, S., Chuansumrit, A., Cianciulli, P., Dauriac, C., Delforge, M., Dölken, G., Dombret, H., Duyster, J., Economopoulos, T., Ehninger, G., Enggaard, L., Fillet, G., Filosa, A., Forni, G., Galanello, R., Gastl, G., Goldfarb, A., Grigg, A., Gumruk, F., S. Y., Ha, Haase, D., Heinrich, B., Hertzberg, M., Ho, J., Hsu, H. C., Huang, S., Hunault Berger, M., Inusa, B., Jaulmes, D., Jensen, J., Kilinc, Y., Kim, K. H., Kinsey, S., Kjeldsen, L., Koren, A., Lai, M. E., Lai, Y., Lee, K. H., Lee, S. H., Legros, L., Li, C., Li, Q., Linkesch, W., Lübbert, M., Lutz, D., Mohamed Thalha, A. J., Mufti, G., Muus, P., Nobile, F., Papadopoulos, N., Perrotta, S., Petrini, M., Pfeilstöcker, M., Piga, A., Poole, J., Porter, J. B., Pungolino, E., Quarta, G., Ravoet, C., Jolimont Lobbes, H. H., Remacha, A. F., Roy, L., Saglio, G., Sanz, G., Schmugge, M., Schots, H., Secchi, G., Shah, F., Shah, H., Shen, Z., Slama, B., Sutcharitchan, P., Tamary, H., Tesch, H. J., Troncy, J., Villegas, A., Wainwright, L., Wassmann, B., Wettervald, M., Will, A., Wörmann, B., Wright, J., Yeh, S. P., Yoon, S. S., Zoumbos, N. S., and Zweegman, S.

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Blood transfusion, Iron Overload, Adolescent, Anemia, Thalassemia, medicine.medical_treatment, Iron chelation therapy, Transfusion medicine, Transfusion-dependent anemias, Hemosiderosis, Iron Chelating Agents, Gastroenterology, Benzoates, Young Adult, IRON CHELATION, Internal medicine, medicine, Humans, Blood Transfusion, Tissue Distribution, SERUM FERRITIN, Chelation therapy, Prospective Studies, Child, Aged, Aged, 80 and over, business.industry, Myelodysplastic syndromes, Deferasirox, Hematology, Middle Aged, Triazoles, medicine.disease, DEFERASOROX, Deferoxamine, Child, Preschool, Ferritins, Female, Original Article, business, TRANSFUSION-DEPENDENT ANEMIAS, Iron, Dietary, medicine.drug
Abstract

Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, is the first to evaluate whether fixed starting doses of deferasirox, based on transfusional iron intake, with dose titration guided by serum ferritin trends and safety markers, provides clinically acceptable chelation in patients (agedor=2 years) with transfusional hemosiderosis from various types of anemia.The recommended initial dose was 20 mg/kg/day for patients receiving 2-4 packed red blood cell units/month and 10 or 30 mg/kg/day was recommended for patients receiving less or more frequent transfusions, respectively. Dose adjustments were based on 3-month serum ferritin trends and continuous assessment of safety markers. The primary efficacy end-point was change in serum ferritin after 52 weeks compared with baseline.The 1744 patients enrolled had the following conditions; thalassemia (n=1115), myelodysplastic syndromes (n=341), aplastic anemia (n=116), sickle cell disease (n=80), rare anemias (n=43) and other transfused anemias (n=49). Overall, there was a significant reduction in serum ferritin from baseline (-264 ng/mL; P0.0001), reflecting dosage adjustments and ongoing iron intake. The most common (5%) adverse events were gastrointestinal disturbances (28%) and skin rash (10%). Conclusions Analysis of this large, prospectively collected data set confirms the response to chelation therapy across various anemias, supporting initial deferasirox doses based on transfusional iron intake, with subsequent dose titration guided by trends in serum ferritin and safety markers (clinicaltrials.gov identifier: NCT00171821).

Published
2009

114. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Author

Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Boekhorst, P. Te, Sanz, G., Del Canizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lubbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T., Hellstrom-Lindberg, E., Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Boekhorst, P. Te, Sanz, G., Del Canizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lubbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T., and Hellstrom-Lindberg, E.

Abstract

Item does not contain fulltext, This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed after 16 weeks. More patients in the lenalidomide 10- and 5-mg groups achieved RBC-transfusion independence (TI) for >/= 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was not reached (median follow-up, 1.55 years), with 60% to 67% of responses ongoing in patients without progression to acute myeloid leukemia (AML). Cytogenetic response rates were 50.0% (10 mg) versus 25.0% (5 mg; P = .066). For the lenalidomide groups combined, 3-year overall survival and AML risk were 56.5% and 25.1%, respectively. RBC-TI for >/= 8 weeks was associated with 47% and 42% reductions in the relative risks of death and AML progression or death, respectively (P = .021 and .048). The safety profile was consistent with previous reports. Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome. This trial was registered at www.clinicaltrials.gov as #NCT00179621.

Published
2011

115. Caractéristiques en TEP au 18F-FDG des mastocytoses systémiques

Author

Djelbani, S., primary, Mekinian, A., additional, Chanderis, M.-O., additional, Monssarat, O., additional, Pop, G., additional, Durieu, I., additional, Georgin-Lavialle, S., additional, Grosboif, B., additional, Beyne-Rauzy, O., additional, Hermine, O., additional, Fain, O., additional, and Soussan, M., additional

Published
2013
Full Text
View/download PDF

118. O-010 Prognostic factors of response to azacitidine (AZA) in low-risk MDS resistant to erythroid stimulating agents (ESA). The GFM Azaepo 08 study

Author

Gardin, C., primary, Thepot, S., additional, Beyne-Rauzy, O., additional, Benabdelali, R., additional, Prebet, T., additional, Park, S., additional, Stamatoulas, A., additional, Guerci-Bresler, A., additional, Cheze, S., additional, Tertian, G., additional, Choufi, B., additional, Legros, L., additional, Bastie, J.N., additional, Delaunay, J., additional, Chaury, M.P., additional, Wattel, E., additional, Dreyfus, F., additional, Preudhomme, C., additional, Vey, N., additional, and Fenaux, P., additional

Published
2013
Full Text
View/download PDF

128. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Author

Damm, F, primary, Thol, F, additional, Kosmider, O, additional, Kade, S, additional, Löffeld, P, additional, Dreyfus, F, additional, Stamatoullas-Bastard, A, additional, Tanguy-Schmidt, A, additional, Beyne-Rauzy, O, additional, de Botton, S, additional, Guerci-Bresler, A, additional, Göhring, G, additional, Schlegelberger, B, additional, Ganser, A, additional, Bernard, O A, additional, Fontenay, M, additional, and Heuser, M, additional

Published
2011
Full Text
View/download PDF

135. 7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry

Author

de Swart, L., primary, Smith, A., additional, Fenaux, P., additional, Symeonidis, A., additional, Hellström-Lindberg, E., additional, Sanz, G., additional, Cermak, J., additional, Georgescu, O., additional, Germing, U., additional, MacKenzie, M., additional, Beyne-Rauzy, O., additional, Malcovati, L., additional, Stauder, R., additional, Droste, J., additional, Bowen, D., additional, and de Witte, T., additional

Published
2011
Full Text
View/download PDF

136. 99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients

Author

Park, S., primary, Sapena, R., additional, Kelaidi, C., additional, Vassilieff, D., additional, Bordessoule, D., additional, Stamatoullas, A., additional, Cheze, S., additional, Beyne-Rauzy, O., additional, Vey, N., additional, Rose, C., additional, Guerci, A., additional, Ame, S., additional, Tercian, G., additional, Slama, B., additional, Fenaux, P., additional, and Dreyfus, F., additional

Published
2011
Full Text
View/download PDF

138. 210 Should immunosuppressive therapy (1ST) be used more often in lower risk MDS?

Author

Cereja, S., primary, Brechignac, S., additional, Adès, L., additional, Braun, T., additional, Boehrer, S., additional, Hebibi, Z., additional, Sapena, R., additional, Beyne-Rauzy, O., additional, Vey, N., additional, Dombret, H., additional, Bordessoule, D., additional, Dreyfus, F., additional, Fenaux, P., additional, and Gardin, C., additional

Published
2011
Full Text
View/download PDF

140. 174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?

Author

Itzykson, R., primary, Thepot, S., additional, Beyne-Rauzy, O., additional, Ame, S., additional, Isnard, F., additional, Salanoubat, C., additional, Taksin, A.-L., additional, Chelgoum, Y., additional, Quesnel, B., additional, Malfuson, J.-V., additional, Legros, L., additional, Vey, N., additional, Turlure, P., additional, Gardin, C., additional, Boehrer, S., additional, Ades, L., additional, and Fenaux, P., additional

Published
2011
Full Text
View/download PDF

141. 219 Long-term outcome of anemic non del 5q lower-risk MDS refractory to or relapsing after erythropoiesis stimulating agents (ESAs)

Author

Kelaidi, C., primary, Park, S., additional, Sapena, R., additional, Beyne-Rauzy, O., additional, Coiteux, V., additional, Vey, N., additional, Stamatoullas, A., additional, Choufi, B., additional, Delaunay, J., additional, Gourin, M.-P., additional, Cheze, S., additional, Ravoet, C., additional, Ferrant, A., additional, Escoffre-Barbe, M., additional, Aljassem, L., additional, Raffoux, E., additional, Itzykson, R., additional, Ades, L., additional, Dreyfus, F., additional, and Fenaux, P., additional

Published
2011
Full Text
View/download PDF

144. 306 Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Author

Kosmider, O., primary, Itzykson, R., additional, Cluzeau, T., additional, Mansat-De Mas, V., additional, Dreyfus, F., additional, Beyne-Rauzy, O., additional, Quesnel, B., additional, Vey, N., additional, Gelsi-Boyer, V., additional, Raynaud, S., additional, Preudhomme, C., additional, Ades, L., additional, Fenaux, P., additional, and Fontenay, M., additional

Published
2011
Full Text
View/download PDF

146. 239 NF-κB regulates FAS gene expression in myelodysplastic syndromes

Author

Ettou, S., primary, Humbrecht, C., additional, Benet, B., additional, Kosmider, O., additional, Baud, V., additional, Mariot, V., additional, Beyne-Rauzy, O., additional, Quesnel, B., additional, Lacombe, C., additional, Dreyfus, F., additional, Mayeux, P., additional, Solary, E., additional, and Fontenay, M., additional

Published
2011
Full Text
View/download PDF

147. 34 Health-related quality of life in low-risk MDS patients from the European LeukemiaNet Registry: Correlation with age, gender and decreased survival

Author

Stauder, R., primary, Smith, A., additional, de Witte, T., additional, Proste, J., additional, Fenaux, P., additional, Symeonidis, A., additional, Hellstrom-Lindberg, E., additional, Sanz, G., additional, Cermak, J., additional, Georgescu, O., additional, Germing, U., additional, Mac Kenzie, M., additional, Beyne-Rauzy, O., additional, Malcovati, L., additional, and Bowen, D., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results